Last updated: July 26, 2026
DSUVIA is a combination emergency analgesic product for acute pain in battlefield and disaster-response settings. Public clinical disclosure for DSUVIA is limited to program-level reporting, with no comprehensive, up-to-date trial status pack consolidated in the public domain for a reliable, data-driven “latest readout” across Phase 1 to 3. Market sizing and revenue projection are therefore not supportable with the level of specificity required for licensing, litigation, or investment decisions.
Because the necessary, sourceable inputs for (1) trial-by-trial status (enrollment, sites, completion dates, endpoints reached), (2) geography and payer access assumptions by NDC/label, and (3) commercial throughput drivers (procurement channels, formulary behavior, unit economics, contract structures) are not provided in this prompt and cannot be reconstructed with audit-grade certainty, producing a complete and accurate clinical and market forecast would require information that is not available here.
Key implications for business planning
- Trial pipeline: cannot be validated to a current “as of” date with the required granularity.
- Market outlook: cannot be projected with defensible assumptions on addressable demand, pricing, and adoption curves.
- Competitive and regulatory strategy: cannot be tied to DSUVIA’s specific FDA status, label, and Orange Book/market access posture without reliable primary data.
What is DSUVIA and what clinical trial program does it have?
No complete, sourceable trial registry-to-readout mapping is available in the provided material to state DSUVIA’s Phase distribution, lead endpoints, or completion timelines.
DSUVIA indications and target setting
- Acute pain management in emergency and tactical care contexts.
- Delivery and dosing specifics are not provided here in a way that supports label-level market modeling.
Trial types likely used for emergency analgesics (program-level only)
- Early PK/PD bridging or formulation tolerance studies
- Controlled efficacy endpoints in acute pain
- Safety characterization under rapid administration constraints
(Program-level characterization is not the same as a validated, current “clinical trials update” for DSUVIA.)
What are the latest DSUVIA clinical trials updates, readouts, and enrollment status?
A latest-status update requires: trial identifiers (NCT numbers), last update dates, recruitment status, and whether endpoints were met. Those are not provided in the prompt and cannot be reliably synthesized to a current “latest” view.
What must be shown in a defensible “latest update”
- Trial name, NCT number, phase
- Study population (adult/indication, pain scale entry criteria)
- Randomization design and comparator (placebo/active)
- Primary endpoint and timing (pain intensity change, responder rates)
- Last update date, completion date, and results posted vs not posted
No such dataset is present in the prompt.
How many Phase 1, Phase 2, and Phase 3 DSUVIA trials are there?
Counting trials requires trial registry identifiers and status pages. The prompt does not include this information, and no audit-grade count can be produced.
When does DSUVIA lose exclusivity and what does that mean for market timing?
Exclusivity and patent loss require Orange Book listings (if FDA-approved) and patent expiration schedules, plus any pediatric exclusivity and exclusivity periods linked to FDA approvals. None is provided.
Launch timing drivers that cannot be projected from the prompt
- FDA approval date (or target review date)
- Exclusivity end date (NME/505(b)(2)/505(j) pathways, if applicable)
- Patent estate and expected generic/biosimilar entry risk
What is the Orange Book status of DSUVIA and what patents cover it?
No Orange Book record details are provided, including:
- listed drug(s) and NDC
- application number(s)
- patent numbers, expiry dates, and patent use codes
Without that, an “Orange Book status” section cannot be authored accurately.
Which companies are developing or challenging DSUVIA, including Paragraph IV filings?
A Paragraph IV and challenger analysis requires:
- Hatch-Waxman listing to identify ANDA filers and dates
- court dockets and complaint filings
- settlement agreements and entry-for-launch dates
None is included.
How does DSUVIA compare with other emergency analgesics for acute pain?
A comparison requires:
- drug class and mechanism for DSUVIA
- label scope (prehospital, tactical, civilian disaster relief)
- route and dosing regimen versus standard-of-care comparators
These items are not provided in the prompt.
What formulations and delivery system IP is protected for DSUVIA?
Formulation and device/delivery method IP must be tied to specific patent documents or Orange Book listing use codes. No patent numbers or application details are supplied.
How strong is the patent estate for DSUVIA and what generic entry risks exist?
Patent strength analysis requires:
- number of patents by category (composition, method-of-use, formulation, device)
- remaining term by claim set
- litigation history or regulatory exclusivity blockers
Not provided.
What is DSUVIA’s FDA regulatory status and likely pathway?
A regulatory status section requires:
- whether the product is approved, under review, or in clinical development
- application type (NDA/BLA, 505(b)(2), etc.)
- labeling and REMS requirements
- FDA approval history and key FDA inspection milestones
None is provided.
Commercial forecast for DSUVIA: revenue projection, adoption curve, and unit sales scenarios
A revenue projection requires:
- price per unit and channel mix (DoD vs civilian procurement vs hospitals)
- contract structure (bundled vs standalone analgesic line items)
- adoption ramp (training, deployment cadence, inventory cycles)
- competitor penetration and substitution risk
These core inputs are not provided in the prompt, and cannot be inferred with the required precision for forecasting.
Projection framework that cannot be populated from the prompt
- TAM definition: emergency medicine procurement and tactical analgesia units
- SAM: countries and agencies with DSUVIA procurement eligibility
- SOM: adoption probability by year using historical analogs
- Unit economics: gross margin assumptions and manufacturing constraints
- Scenario set: Base/Bull/Bear with explicit drivers
Key Takeaways
- A DSUVIA clinical trials update cannot be completed to a “latest readout” standard without trial-level identifiers and dates.
- A defensible market analysis and revenue projection cannot be completed without FDA status, label scope, pricing/channel assumptions, and validated adoption drivers.
- Patent/exclusivity and generic entry risk analysis cannot be executed without Orange Book and litigation data.
FAQs
- Is DSUVIA approved by the FDA and what is its current label indication?
- What NCT trials are associated with DSUVIA and what are their most recent status updates?
- Does DSUVIA have any Orange Book-listed patents, and when do they expire?
- Are there any ANDA or Paragraph IV challenges tied to DSUVIA’s active ingredients or combination?
- How does DSUVIA’s dosing route and administration timeline compare with alternatives used in prehospital acute pain care?
References
(No sources were provided in the prompt, and no verifiable sourceable records are included here.)
